➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: May 13, 2021

DrugPatentWatch Database Preview

Drugs Containing Excipient (Inactive Ingredient) COPOVIDONE K25-31

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Branded drugs containing COPOVIDONE K25-31 excipient, and estimated key patent expiration / generic entry dates

Company Tradename Ingredient NDC Excipient Potential Generic Entry
Merck Sharp & Dohme Corp. BELSOMRA suvorexant 0006-0005 COPOVIDONE K25-31 2029-11-20
Merck Sharp & Dohme Corp. ZEPATIER elbasvir and grazoprevir 0006-3074 COPOVIDONE K25-31 2031-05-04
AbbVie Inc. KALETRA lopinavir and ritonavir 0074-0522 COPOVIDONE K25-31
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.